Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Novo Nordisk

258.25 DKK+0.90 %15.10. klo 13.46
1,109 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.90 %
-7.90 %
-19.22 %
+4.92 %
-20.60 %
-28.39 %
-63.96 %
-20.13 %
+20,642.97 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.15T DKK
Turnover
290.51M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
ShowingAll content types

Forum discussions
China’s drug regulator has accepted the marketing authorization application for Novo’s oral weight-loss drug Wegovy. The company is eager to compete in the rapidly growing market, particularly against Eli Lilly. Novo Nordisk said on Thursday that China’s drug regulator accepted its...
8/27/2026, 2:43 PM
by Sijoittaja-alokas
16
This is also being seen in Finland. According to a recent news article, Stora Enso ran a year-long pilot and provided Ozempic to its employees. Among others, the chief shop steward lost around 30 kilos in the trial: Ilta-Sanomat – 12 Oct 26 Jättiyritys tarjosi työntekijöilleen Ozempicia...
yesterday
by Timo Huhtamäki
13
Farma likes to often present these “changing improves results” findings. Paradoxically, usually changing does improve them. The explanation is the so-called regression to the mean phenomenon, meaning the switch is usually preceded by a situation where the medication hasn’t worked...
9/30/2026, 1:42 PM
by Clark kent
13
Novo’s CMD in London. The market side isn’t very convinced (-5%). The press release on the main points of the CMD was at least quite high-level jargon. Key highlights of the strategic ambitions for 20301 are: Grow and diversify pipeline Launch >5 multi-blockbusters by 2030 and deliver...
9/21/2026, 9:16 AM
by Cotr
10
Inderes Novo Nordisk enters next chapter to bring better health to more people,... Bagsværd, Denmark, 14 September 2026 – Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name, ... Corporate...
9/14/2026, 7:19 AM
by Gwertheney
10
And the German market seems to have opened today, sales are certainly massive and profits handsome, but still, there should be a couple more pillars to support this business. GLP-1 pills are not quite enough for a new rise for Novo. https://www.reuters.com/legal/litigation/novo-nordisk...
9/1/2026, 9:55 AM
by Keepitcoming
8
Not exactly huge news, but perhaps quite interesting. Walmart plans to offer its employees over 250 prescription drugs for free, including Ozempic and Mounjaro for the treatment of Type 2 diabetes, though coverage naturally requires some sort of “prior approval.” Walmart Inc (NASDAQ...
yesterday
by Sijoittaja-alokas
7
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.11.
2026

Interim report Q3'26

Regulatory press release12.10.2026 klo 13.28

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release05.10.2026 klo 15.32

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk
Regulatory press release02.10.2026 klo 23.53

Novo provides update on the denecimig Biologics License Application (BLA) in the US

Novo Nordisk

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release01.10.2026 klo 13.45

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026

Novo Nordisk
Press release30.09.2026 klo 15.30

Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026

Novo Nordisk
Regulatory press release28.09.2026 klo 16.49

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release22.09.2026 klo 15.00

Novo and UNICEF expand partnership to support a healthier start for more than 80 million children

Novo Nordisk
Regulatory press release21.09.2026 klo 15.37

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release21.09.2026 klo 13.24

Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial

Novo Nordisk
Press release21.09.2026 klo 11.00

Highlights to be presented at Novo’s Capital Markets Day 2026

Novo Nordisk
Press release18.09.2026 klo 13.36

Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)

Novo Nordisk
Regulatory press release17.09.2026 klo 17.14

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A

Novo Nordisk
Press release16.09.2026 klo 15.00

Novo and Anthropic will collaborate to advance drug discovery with Claude

Novo Nordisk
Press release16.09.2026 klo 10.00

Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026

Novo Nordisk
Regulatory press release14.09.2026 klo 16.13

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release14.09.2026 klo 10.05

Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture

Novo Nordisk
Regulatory press release07.09.2026 klo 14.12

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release07.09.2026 klo 13.00

Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification

Novo Nordisk
Regulatory press release31.08.2026 klo 14.16

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release24.08.2026 klo 16.51

Novo Nordisk A/S - share repurchase programme

Novo Nordisk